Hepatic artery infusion chemotherapy for liver malignancy.

Abstract

To date, hepatic artery infusion (HAI) chemotherapy has primarily been investigated in the setting of colorectal cancer liver metastases (CRLM). Few studies have been conducted in North America regarding HAI chemotherapy for primary liver cancers (PLC) or noncolorectal liver metastases (non-CRLM). Despite decades of evaluation, controversy surrounding the use of HAI chemotherapy still exists. In this article the methods of HAI chemotherapy delivery, technical aspects of catheter and pump insertion, and specific complications of HAI chemotherapy are discussed. Outcomes of clinical trials and reviews of HAI chemotherapy in the setting of CRLM, PLC, and non-CRLM are evaluated.

• Authors: Julie N Leal, T Peter Kingham
• Journal: Surgical oncology clinics of North America (Surg Oncol Clin N Am) Vol. 24 Issue 1 Pg. 121-48 (Jan 2015) ISSN: 1558-5042 [Electronic] United States
• PMID: 25444472 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (administration & dosage)
• Hepatic Artery
• Humans
• Infusions, Intra-Arterial
• Liver Neoplasms (drug therapy)